But did that study show more approvals on the first resub, the second, or both? Perhaps there isn't a significant increase in the number of approvals upon the second resub, and therefore it's not worth the additional work/cost on everyone's part? Meg -- Margaret Bouvier, Ph.D. Medical and Science Writing, Editing, Advising Grants * Publications * Communications * Policy xxxxxx@comcast.net * 413.230.6523 > what's weird is NIH's own study showed that resubmissions result in more > approvals, esp. for clinical studies. > puzzling. > > > > > > -----Original Message----- > From: Kiss, Helen G. Dr. <xxxxxx@MUOHIO.EDU> > To: xxxxxx@hrinet.org > Sent: Wed, 8 Oct 2008 11:55 am > Subject: Re: [RESADM-L] New NIH Policy on Resubmission (Amended) Applications > > > > > > > > > > > > > > > > > > > > > > > > > The NIH link is: > http://grants.nih.gov/grants/guide/notice-files/NOT-OD-09-003.html > > > > > > > Helen G. Kiss, Ph.D. > > > > Assistant Director & Information Coordinator > > > > Miami University > > > > Office for the Advancement of Research & Scholarship, > > > > 102 Roudebush Hall, > > > > Oxford, OH 45056 > > > > xxxxxx@muohio.edu > > > > �� > > > > (P) 513-529-3600 > > > > (F) 513-529-3762 > > > > �� > > > > The > mission of the Office for the Advancement of Research & Scholarship (OARS) > is to encourage, facilitate, and support the Miami University community in its > effort to obtain external funding for all forms of research, education, > scholarly, creative, service, and outreach activities. > > > > �� > > > > > > > �� > > > > > > > > > > From: Research > Administration List [mailto:xxxxxx@hrinet.org] On Behalf Of Carolyn > Elliott-Farino > > Sent: Wednesday, October 08, 2008 11:46 AM > > To: xxxxxx@hrinet.org > > Subject: Re: [RESADM-L] New NIH Policy on Resubmission (Amended) > Applications > > > > > > > > > > �� > > > > > > > Robert, > > > > > > > > > > �� > > > > > > > > > > Thanks for the info. > I was surprised I hadn't seen the notice and I just logged onto to NIH and > unde > r their policy notices the latest one listed is NOT-OD-09-002. How did you > get this one already? > > > > > > > > > > �� > > > > > > > > > > Carolyn > > > > >>> xxxxxx@IUPUI.EDU 10/8/2008 10:42:15 AM >>> > > > > > > > > > > NIH has revised its > renewal policy from three strikes to "two strikes and you're out." > > > > Currently funded projects will be grandfathered to allow three attempts for > continued funding but they won't accept any -A2 applications after January 7, > 2011. > > > > 1st try: R01AA012345-06 > > 2nd try: R01AA012345-06A1 > > 3rd try: R01AA012345-06A2 (NLT 7 Jan 11) > > > > Robert Aull > > Indiana University > > > > > > New NIH Policy on Resubmission (Amended) Applications > > ---------------------------------------------------------------------------- > > > > Notice Number: NOT-OD-09-003 > > > > Key Dates > > Release Date:�� October 8, 2008 > > > > Issued by > > National Institutes of Health (NIH), (http://www.nih.gov) > > > > Purpose > > > > NIH announces a change in the existing policy on resubmission (amended) > > applications (see http://grants.nih.gov/grants/policy/amendedapps.htm). > > Beginning with original new applications (i.e., never submitted) and > > competing renewal applications submitted for the January 25, 2009 due dates > > and beyond, the NIH will accept only a single amendment to the original > > application.�� Failure to receive funding after two submissions (i.e., the > > original and the single amendment) will mean that the applicant should > > substantially re-design the project rather than simply change the application > in response to previous reviews.�� It is ex > pected that this policy will lead > to funding high quality applications earlier, with fewer resubmissions. > > > > Background > > > > Following the release of the Peer Review Report that was drafted with > > extensive consultation with the external community, Dr. Zerhouni, NIH > > Director, established a Peer Review Oversight Committee (PROC) to finalize > > the recommendations and begin immediate implementation of those > > recommendations.�� Of particular concern was the marked reduction in the > > number of awards made in response to original applications.�� An increasing > > number of projects were funded only after one or more > resubmissions.���� In > > periods of constricted funding, a greater number of projects require > > resubmission, and review committees are more likely to show greater > > preference for amended applications.�� These trends have increased the time > > from original submission to award and the number of submissions per > > investigator. As a result, there has been greater burden placed on applicants > and reviewers as well as a delay in funding for meritorious science. > > > > To change this trend and increase the likelihood that meritorious original > > applications will be funded, the NIH will decrease the number of amendments > > allowed.�� Accordingly, the NIH will begin to phase out second amendment > > applications starting with the January 25, 2009 due date. This policy will > > increase the numbers of high quality original and first amendments that can > > be funded earlier. > > > > NIH Policy on Resubmission (Amended) Applications > > > > > Beginning with applications intended for the January 25, 2009 due date, all > > original new applications (i.e., never submitted) and competing renewal > > applications will be permitted only a single amendment (A1).�� For this and > > subsequent cohorts of original new and competing renewal applications, any > > second amendment (A2) will be administratively withdrawn and not accepted for > review.���� Applicants who fail to receive funding after two > submissions may resubmit but only if the application is fundamentally revised > to qualify as new.�� A new application is expected to be substantially different > in content and scope with more significant differences than are normally > encountered in an amended application.�� Note that there is no time limit > for the submission of the original and subsequent A1. > > > > Original new and competing renewal applications that were submitted prior to > > January 25, 2009 will be permitted two amendments (A1 and A2).�� For these > > "grandfathered" applications, NIH expects that any A2 will be > submitted no > > later than January 7, 2011, and NIH will not accept A2 applications after > > that date. > > > > This policy applies to all applications, including applications submitted > > under the NIH Small Business Innovation Research (SBIR) and Small Business > > Technology Transfer (STTR) programs, Career Development Awards, Individual > > Fellowships, Institutional Training Grants, Resource Grants, Program > > Projects, and Centers.�� Currently no amendments are permitted for > > applications received in response to a Request fo > r Applications (RFA) unless > > it is specified in the Funding Opportunity Announcement, in which case only > > one amendment will be permitted.�� ations (RFA) unless it is specified in > the > > Funding Opportunity Announcement, in which case only one amendment will be > > permitted. > > > > Inquiries > > > > Applicants are strongly encouraged to discuss their questions with their NIH > > IC contact.�� For additional information or questions, please contact: > > > > Division of Receipt and Referral > > Center for Scientific Review > > 6701 Rockledge Drive MSC 7720 > > Bethesda, MD�� 20892-7720 > > Voice:�� (301) 435-0715 > > Fax:�� (301) 480-1987 > > > > Or send an email to xxxxxx@mail.nih.gov. > > > > Clinicalmail is a service provided by the Association of American Medical > Colleges > > > > > > ====================================================================== > > Instructions on how to use the RESADM-L Mailing List, including > > subscription information and a web-searchable archive, are available > > via our web site at http://www.hrinet.org > (click on "Listserv Lists") > > ====================================================================== > > > > > > > ====================================================================== > Instructions on how to use the RESADM-L Mailing List, incl > uding subscription > information and a web-searchable archive, are available via our web site at > http://www.hrinet.org (click on "Listserv Lists") > ====================================================================== > > > > > > > > > > > ====================================================================== > Instructions on how to use the RESADM-L Mailing List, including > subscription information and a web-searchable archive, are available > via our web site at http://www.hrinet.org (click on "Listserv Lists") > ====================================================================== > > > > > > > > > > > ====================================================================== > Instructions on how to use the RESADM-L Mailing List, including > subscription information and a web-searchable archive, are available > via our web site at http://www.hrinet.org (click on "Listserv Lists") > ====================================================================== > ====================================================================== Instructions on how to use the RESADM-L Mailing List, including subscription information and a web-searchable archive, are available via our web site at http://www.hrinet.org (click on "Listserv Lists") ======================================================================
